Rosanne Fidelus-Gort

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Benjamin M. Segal, Cris S. Constantinescu, Aparna Raychaudhuri et al. · The Lancet Neurology · 2008 · 477 citations

Life Sciences, Immunology, Neurology +14

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Edward Keystone, Peter C. Taylor, Edit Drescher et al. · Annals of the Rheumatic Diseases · 2014 · 282 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Robert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort et al. · Journal of Dermatological Treatment · 2016 · 84 citations

Medicine, Pharmacology, Pharmacotherapy +13

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

M. C. Genovese, Ed Keystone, P. W. J. Taylor et al. · Oxford University Research Archive (ORA) (University of Oxford) · 2012 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +16